Opko Health, INC Form 4 insider transactions

Phillip Frost, along with Frost Gamma Investments Trust, reports acquiring OPKO Health common stock and convertible notes, reflecting changes in beneficial ownership.

OPKO Health's CEO and Chairman, Phillip Frost, through related trusts, acquired 47,537 shares of common stock at a weighted average price of $1.4738 per share.

OPKO Health's CEO and Chairman, Phillip Frost, acquired 150,000 shares of common stock at a weighted average price of $1.4695 per share on January 17, 2025.

Phillip Frost, CEO and Chairman of OPKO Health, purchased 500,000 shares of the company's common stock at a weighted average price of $1.4817 on January 15, 2025.

OPKO Health's CEO and Chairman, Phillip Frost, through related entities, acquired 125,000 shares of common stock in a series of transactions on December 13, 2024.

Phillip Frost's Frost Gamma Investments Trust purchased 500,000 shares of OPKO Health at an average price of $1.5621 per share.

OPKO Health's CEO and Chairman, Phillip Frost, through related trusts, acquired 199,072 shares of common stock at an average price of $1.534 per share.

OPKO Health's CEO, Phillip Frost, through various trusts, acquired 100,000 shares of common stock at an average price of $1.59.

OPKO Health's CEO and Chairman, Phillip Frost, has increased his holdings in the company through a series of transactions, including a direct purchase of 280,183 shares.

OPKO Health's CEO and Chairman, Phillip Frost, acquired 100,000 shares of common stock at an average price of $1.6198 per share on November 14, 2024.

OPKO Health's CEO, Phillip Frost, through various trusts, acquired 280,183 shares of OPKO stock at an average price of $1.5045 on November 8, 2024.

Phillip Frost, along with Frost Gamma Investments Trust, reports changes in beneficial ownership of OPKO Health, Inc. securities, including convertible notes and common stock.

Phillip Frost, along with Frost Gamma Investments Trust, amended their filing regarding beneficial ownership in OPKO Health, citing transactions involving convertible notes.

Phillip Frost, through Frost Gamma Investments Trust, acquired $1.155 million in OPKO Health's 3.75% Convertible Notes due 2029, while disclaiming beneficial ownership of existing common stock holdings except for pecuniary interest.

Opko Health, a significant shareholder of GeneDx Holdings Corp., has sold a portion of its Class A Common Stock in a series of transactions.

Opko Health, a 10% owner of GeneDx Holdings Corp., sold a significant number of Class A Common Stock shares over two days in August 2024.

Opko Health, a significant shareholder of GeneDx Holdings Corp., has sold a portion of its Class A Common Stock in two transactions.

OPKO HEALTH, INC. reports the sale of 88,839 shares of GeneDx Holdings Corp. Class A Common Stock at an average price of $33.5027 on July 31, 2024.

Opko Health, a significant shareholder in GeneDx Holdings Corp., recently sold 50,000 shares of Class A Common Stock at an average price of $33.8578.

Opko Health, a significant shareholder of GeneDx Holdings Corp., has sold a portion of its Class A common stock in two transactions.

Phillip Frost, CEO and Chairman of OPKO Health, Inc., reports the acquisition of 500,000 shares of common stock and adjustments to his beneficial ownership.

Jane Hsiao, Vice Chairman & CTO of OPKO Health, reports acquiring 500,000 shares of common stock on July 24, 2024.

Adam Logal, CFO of OPKO Health, reports acquiring 437,500 shares of common stock and disposing of an unspecified amount in a recent transaction.

Steven D. Rubin, Executive VP-Administration at OPKO Health, Inc., acquired 437,500 shares of common stock on July 24, 2024.

Elias Zerhouni, Vice Chairman and President of OPKO Health, reports the acquisition and disposal of OPKO common stock and restricted stock units.

Gary J. Nabel, Chief Innovation Officer at OPKO Health, reports the acquisition of 437,500 shares of common stock and indirect ownership of millions of shares through various trusts and entities.

Opko Health, a significant shareholder of GeneDx Holdings Corp., has sold a portion of its Class A Common Stock in a series of transactions.

Opko Health, a significant shareholder in GeneDx Holdings Corp., sold 25,000 shares of Class A Common Stock at an average price of $32.9275 on July 17, 2024.

Opko Health, a significant shareholder in GeneDx Holdings Corp., sold 36,118 shares of Class A Common Stock at an average price of $28.2412 on July 5, 2024.

OPKO Health, a significant shareholder of GeneDx Holdings Corp., has sold a portion of its Class A Common Stock over three days in July 2024.